Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4100)	3/16/2006 1:54:50 PM
From: Doc Bones	Read Replies (4) \| Respond to of 12215

Nice performance Rick! I don't know if we'll beg for it, but maybe we'll have to settle for Jim Cramer. Doc *** 3-15 The mantra "buy low and sell high" is a bit misleading, Cramer said, because it's often taken to mean that investors should buy only when stocks are down and only sell when they're up. You can't always get in on a stock at the bottom and sometimes you have to cut your losses and sell because there's no way the stock you own will go higher, he said. "But if you see weakness in a stock you want ... then you absolutely must buy into weakness and wait to sell into some strength," he said, and that's why he believes now is the time to buy Solexa (SLXA). Cramer has been waiting for the stock to come down from its high around $12, and now that it's at $8 and change, he said to look into the gene-sequencing company. Solexa has a new machine to roll out that reads DNA. The machine also has a range of uses outside of DNA reading, Cramer said, and he believes that it is faster, cheaper and more productive than other options. He said that there's no comparison between Solexa and Human Genome Sciences (HGSI), a company that he called a "serial disappointer." Human Genome starts with already decoded DNA and then uses that information to develop medicines, while Solexa reads the DNA. Bear DNA AVII MDT --- 3-14 And he told another caller that he would stay away from Sepracor (SEPR) because of recent bad publicity. Bull VPHM ZGEN RAD WAG --- 3-13 More Vanity Fare Lots of people are turning 60 every day, and none of them wants to look their age, Cramer said. That's why he likes AngioDynamics (ANGO), a company that has lots of products to keep people looking young. He believes that the company's treatments for varicose veins make up the part of the business to look at, even though it also makes products for fairly serious vascular disorders. "Treating actual problems doesn't make the big moolah. Making people look better is the better way to make a lot of money," he said. Its varicose treatment is a minimally invasive procedure and should continue to grow at 20% a year, Cramer said, adding that Wall Street values growth above all things. Angio makes the equipment for varicose laser therapy -- one of the most popular treatments -- and Cramer said that all kinds of doctors offer the procedure. Treating varicose veins has become very popular and widespread, and this helps raise margins for doctors who are in a margin squeeze, he added. He believes that the company has an "ace in the hole" drug to treat spider veins and that even though Angio trades at a premium it's a best-of-breed company that is growing its earnings at 30%. Bull AMGN CEPH SGP JNJ Bear CELG MDCO GTOP